Current Gene Therapy

Our screening flags Current Gene Therapy as a possible predatory venue because its publisher appears on Beall's archive, which has been frozen since 2017. Treat this as a prompt to check carefully, not a verdict: verify against DOAJ and Think. Check. Submit before submitting.

Per our venue index, Current Gene Therapy appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.

Papers in Current Gene Therapy are cited about 4.0 times each within two years of publication, and Scimago places it in Q2, with an h-index of 90. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.

In the Scimago Journal Rank 2025 edition, Current Gene Therapy is Q2 in 2 of its 5 subject categories and Q3 in the other 3. By category: Drug Discovery: Q2, #62 of 161; Genetics: Q2, #185 of 370; Genetics (clinical): Q3, #55 of 103; Molecular Medicine: Q3, #104 of 181; Molecular Biology: Q3, #243 of 425. Its best category quartile is Q2. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Current Gene Therapy is cited about 4.0 times per paper over two years, with an h-index of 90.

The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Current Gene Therapy. The open equivalent is its best Scimago quartile, Q2 in Drug Discovery and 1 other category, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.

Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.